CSF1

colony stimulating factor 1

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CSF1 Overexpression1
Pexidartinib	Tenosynovial Giant Cell Tumor	Predictive	B	Supports Sensitivity Response	3	submitted	EID1969 23 patients were enrolled in the phase 2 extension study. The chosen phase 2 dose of PLX3397 was 1000 mg per day. 12/23 patients with tenosynovial giant-cell tumors had a partial response and 7 patien… (full text at CIViC) PMID 26222558 · Tap et al., 2015 · Open in CIViC	civic

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Pheochromocytoma and Paraganglioma TCGA-PCPG	ParagangliomaCURATED_BROADER

Literature

Data not yet available

No publication linked to this gene yet.